Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease (ACHIEVE)

Study Lead

Dr. Michael Walsh

McMaster University


Individuals receiving dialysis are at risk of heart failure and heart related death. There is an urgent need for treatments that reduce the risk of these problems in patients that require dialysis.

Spironolactone is a pill used to prevent heart failure and related deaths in patients that do not require dialysis. It works by blocking a hormone (aldosterone) in your body that causes high blood pressure and can damage the heart. Although spironolactone is very effective in patients that do not require dialysis, we do not know if spironolactone is effective in dialysis patients. Our research will help determine if spironolactone reduces heart failure and heart related deaths in dialysis patients.

The purpose of this study is to determine if spironolactone reduces death or hospitalization for heart failure and is well tolerated in patients that require dialysis.


Inclusion Criteria:

  1. Age
    1. ≥45 years or
    2. ≥18 with a history of diabetes
  2. On dialysis ≥ 90 days
  3. On either
    1. Hemodialysis prescribed at least 2 treatments per week or
    2. Peritoneal dialysis prescribed with at least 1 exchange daily
  4. Provides informed consent

Exclusion Criteria:

  1. Hyperkalemia
    1. Serum potassium >5.8 mmol/L in the 6 weeks prior to enrollment or
    2. Serum potassium >6.0 mmol/L during active run-in
  2. Currently taking and unable to withdraw a mineralocorticoid receptor antagonist (i.e. spironolactone or eplerenone).
  3. Known sensitivity or allergy to spironolactone
  4. Current or planned pregnancy or breastfeeding
  5. Scheduled living related donor renal transplant
  6. Life expectancy < 6 months in the opinion of a treating nephrologist.
  7. Enrolled in another interventional trial testing a mineralocorticoid receptor antagonist or drug that has a known or likely interaction with spironolactone.
  8. Treating physician believes either spironolactone is either absolutely indicated or absolutely contra-indicated

Type of Participation

Clinical Trial


Chronic Kidney Disease

Related Condition

Diabetes, Heart Disease


Hemodialysis, Peritoneal Dialysis


All provinces and territories

Related studies

  • Food Insecurity and Diet Quality in Adults with Chronic Kidney Disease

    Overview: Researchers at the University of Alberta are studying the impact of food insecurity on the diets and kidney health of Canadian adults with CKD.

    Study type: Interview

    April 18, 2024

  • Call for Applications for the Kidney Foundation of Canada Patient Community Advisory Network(PCAN)


    Study type: Focus Group, Patient Partnership

    April 16, 2024

  • Mind the Gap: Addressing Mental Health Care Gaps for Canadians Receiving Facility-Based Hemodialysis

    Overview: This survey is seeking perspectives on the gaps and needs in the current delivery of mental healthcare for people on hemodialysis, as well as suggestions to improve the current status quo.

    Study type: Survey

    March 26, 2024